Your browser version is outdated. We recommend that you update your browser to the latest version.
Νεώτερα από την Ενδοκρινολογία


Οι επισκέπτες μέσα από την ιστοσελίδα αυτή μπορούν να ενημερώνονται για τα νεώτερα κλινικά δεδομένα και τις εξελίξεις στην Ενδοκρινολογία που προκύπτουν και τους αφορούν. 



►January 02, 2018

Myo-inositol plus selenium supplementationrestores euthyroid state in Hashimoto’s


Selenium is an essential trace element for humans; selenium dependent enzymes exert antioxidant and anti-inflammatory properties. It has been shown to reduce the inflammatory status in patients with chronic autoimmune thyroiditis.

Myoinositol is a carbocyclic polyol precursor of phosphoinositide synthesis; it is involved in cell signaling and, precisely, as a second messenger regulating the activities of several hormones such as TSH, follicle-stimulating hormone (FSH) and insulin.

Though L-T efficacy is well recognized as a treatment when the TSH level is above 10 μIU/ml, it is still disputed for patients with serum TSH levels lower than 10 μIU/ml. The present trial confirms that the combined treatment, Myoinositol plus Selenium, is effective in significantly reducing the TSH and autoantibodies values in chronic autoimmune thyroiditis, thus improving the well-being of patients and restoring the euthyroid state in Hashimoto’s subjects with Subclinical Hypothyroidism.


M. Nordio, S. Basciani. Myo-inositol plus selenium supplementation restores euthyroid state in Hashimoto’s patients with subclinical hypothyroidism. European Review for Medical and Pharmacological Sciences. 2017; 21 (2 Suppl): 51-59


►January 02, 2019

Thyroid Nodule Size Irrelevant When It Comes to Malignancy


Rates of malignancy and false-negative FNA results vary but, in most studies, are not higher in larger nodules. Patients with large, cytologically benign thyroid nodules need not undergo immediate surgical resection, as false-negative FNA rates are low and are expected to decrease in light of nomenclature revision of a subset of follicular variants of papillary thyroid carcinoma.

►Thyroid: Vol. 28, No. 12



►January 08, 2019

Persistent Hot Flashes Increase Breast Cancer Risk in Women


Postmenopausal women who experience persistent hot flashes are more likely to be diagnosed with breast cancer than women who never experience vasomotor symptoms, but they are not more likely to die from it, a new long-term analysis from the Women's Health Initiative suggests.

Menopause: December 28, 2018 - Volume Publish Ahead of Print - Issue - p


►January 09, 2019

Osteoporosis Drug Romosozumab Gains First Approval, in Japan

The osteoporosis drug romosozumab (Amgen/Astellas BioPharma) has been approved in its first market worldwide, in Japan, for the treatment of osteoporosis in women at high risk of fracture, where it will be known as Evenity, the companies have announced.

►August 1, 2020

Low Vitamin D Linked to Increased COVID-19 Risk

Τα χαμηλά επίπεδα βιταμίνης D στο πλάσμα εμφανίστηκαν ως ανεξάρτητος παράγοντας κινδύνου για τη μόλυνση από το COVID-19 σε μια πρόσφατη μεγάλη μελέτη.

Οι συμμετέχοντες που ήταν θετικοί για το COVID-19 είχαν 50% περισσότερες πιθανότητες να έχουν χαμηλά έναντι φυσιολογικών επιπέδων 25 (OH) D.


Eugene Merzon, Dmitry Tworowski, Alessandro Gorohovski, Shlomo Vinker, Avivit Golan Cohen,  Ilan Green,  Milana Frenkel Morgenstern. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID‐19 infection: an Israeli population‐based study. The FEBS journal. 23 July 2020



Phentermine-Topiramate May Be Best Medication for Weight Loss

Shi Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2021. Dec 8;S0140-6736(21)01640-8


Of all the available medications for treatment of overweight and obesity, phentermine-topiramate (Qsymia), followed by glucagon-like peptide 1 (GLP-1) receptor agonists, may be the most effective for weight loss, a systematic review and network meta-analysis of randomized controlled trials suggests.

Researchers examined data from 143 clinical trials, with a total of 49,801 participants, that assessed the proportion of patients who achieved at least a 5% weight reduction on different medications as compared with lifestyle interventions.

When researchers examined three GLP-1 receptor agonists separately, they found the largest likelihood of a weight reduction of 5% or more relative to lifestyle interventions with semaglutide (OR 9.82), followed by liraglutide (OR 4.91), and exenatide (OR 2.86).

Phentermine and topiramate capsules are used to help adults who are obese or who are overweight and have weight-related medical problems to lose weight and to keep from gaining back that weight. Phentermine and topiramate extended-release capsules must be used along with a reduced calorie diet and exercise plan. Phentermine is in a class of medications called anorectics. It works by decreasing appetite. Topiramate is in a class of medications called anticonvulsants. It works by decreasing appetite and by causing feelings of fullness to last longer after eating.